Bloomberg News and Videos — Page 356

Heather Conley, Nonresident Senior Fellow at AEI and Former Deputy Assistant Secretary of State for the Bureau of European and Eurasian Affairs says because Iran controls the Strait of Hormuz, they have a strategic advantage.

Jay Ritter, University of Florida emeritus professor and director of the IPO Initiative, known as "Mr. IPO" for his work on initial public offerings, joins Caroline Hyde and Ed Ludlow on "Bloomberg Tech." to discuss SpaceX's IPO. It is set to be "the largest private-sector company ever to go public," for the broader tech IPO landscape, he says.

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion, leveraging its obesity-fueled dominance to establish itself as a leader in other areas and become a major player in infectious diseases.  The agreements with Curevo, LimmaTech Biologics and Vaccine Company give Lilly access to novel technology and experimental immunizations for shingles, common bacterial pathogens and Epstein-Barr virus, according to a statement on Tuesday.  "These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences," Dan Skovronsky, Lilly's chief scientific and product officer, said in a statement.  Bloomberg News Health Reporter, Madison Muller, joins Paul Sweeney and Alexis Christoforous on "Bloomberg Intelligence" to analyze what's next for Eli Lilly after agreeing to buy three vaccine developers.

Qualcomm will supply chips to TikTok owner ByteDance for artificial intelligence data centers, according to people familiar with the matter. Ian King helped break the story and he reports on "Bloomberg Tech."

The AI data center boom is becoming an industrial arms race. CyrusOne CEO Eric Schwartz joined Bloomberg Open Interest to explain why the future of AI depends on power grids, skilled labor, and trillion-dollar infrastructure bets.

Wall Street's AI boom is spilling into credit markets. As hyperscalers' issue huge amounts of debt, banks are buying protection to manage exposure, while hedge funds sell that protection for what looks like easy money. But if the AI race starts producing winners and losers, this quiet CDS trade could become much riskier.

Eli Lilly is developing a groundbreaking one-time gene-editing treatment that could permanently lower bad cholesterol and reduce heart disease risk. Bloomberg's Madison Muller joins Open Interest to break down the science, the risks, and why Lilly is racing to expand beyond obesity drugs into its next major growth era.

Ferrari's first fully electric car is already dividing fans. Critics say the $640K EV looks more like a Nissan Leaf or "a bar of soap" than a Ferrari, but the company may not care. Bloomberg's Craig Trudell joins Open Interest to explain why Ferrari only needs a handful of wealthy buyers to make the Luce a success, and how the brand could use the EV to unlock access to future supercars.

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports.

On this episode of Stock Movers: - AutoZone (AZO) shares fall after the retailer of automotive replacement parts posted comparable sales for the third quarter that fell short of Wall Street's expectations. - Ferrari (RACE IM) shares fell almost 8% after critics panned the look of its first fully electric vehicle, a setback for the Italian super-car maker's controversial push into EVs. - Eli Lilly (LLY) agreed to buy three vaccine developers for as much as $3.8 billion, marking the drugmaker's re-entry into the infectious disease space.